Drug Pipeline

Romiplostim N01 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
23
Active Studies
14
Recruiting
4
Phase 3
10
Top Sponsors
8
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-12 NCT07421167
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice…
date change Primary completion pushed: 2027-03-03 -> 2029-01-10
2026-06-12 NCT07421167
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice…
date change Completion pushed: 2027-03-31 -> 2030-09-18
2026-06-05 NCT07523009
CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAA
overall status: "Not Yet Recruiting" → "Withdrawn"
2026-06-05 NCT07523009
CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAA
critical why stopped: null → "The registration of this research plan was incorrect. A new registration has been re-applied for."
2026-06-05 NCT07523009
CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAA
Enrollment reduced: 43 -> 0 participants
2026-06-05 NCT07532408
Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA
overall status: "Not Yet Recruiting" → "Withdrawn"
2026-06-05 NCT07532408
Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA
critical why stopped: null → "The registration of this research plan was incorrect. A new registration has been done."
2026-06-05 NCT07532408
Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA
Enrollment reduced: 43 -> 0 participants
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-05-28 NCT07612319 Romiplostim for Oral TPO-RA Resistant ITP Recruiting
2026-05-22 NCT07600905 Avatrombopag for Severe Thrombocytopenia After Liver Transplantation: A Retrospective… Completed
2026-05-14 NCT07586813 Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia… Phase 2 Recruiting
2026-05-14 NCT07586826 Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia… Phase 2 Recruiting
Active Studies by Phase
Phase 4
1
Phase 3
4
Phase 2
13
Phase 1/2
1
Phase 1
2
Early Phase 1
1
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT04518475 Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune… Primary Immune Thrombocytopenia (ITP) Recruiting
Phase 3
NCT06759636 A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared… CTIT: Cancer Therapy Induced Thrombocytopenia Recruiting
NCT07345000 A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe… Treatment-naïve Severe Aplastic Anemia Not Yet Recruiting
NCT03937154 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With… Chemotherapy-induced Thrombocytopenia Active, Not Recruiting
NCT05653219 A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in… Primary Immune Thrombocytopenia Active, Not Recruiting
Phase 2
NCT04304820 Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive… Severe Aplastic Anemia Recruiting
NCT06345495 High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients… Splenomegaly Recruiting
NCT07278661 Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. Chirurgical Intervention Recruiting
NCT07400341 Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA MDS (Myelodysplastic Syndrome) Recruiting
NCT07043894 Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients Solid Tumors Recruiting
NCT07586813 Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia… Persistent Isolated Chemotherapy-Induced Thrombocytopenia Recruiting
NCT07586826 Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia… Persistent Isolated Chemotherapy-Induced Thrombocytopenia Recruiting
NCT07421167 A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice… Primary Immune Thrombocytopenia (ITP) Recruiting
NCT07400250 Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With… Primary Immune Thrombocytopenia (ITP) Not Yet Recruiting
NCT05772546 Avatrombopag vs. Placebo for CIT in GI Malignancies Gastrointestinal Cancer Active, Not Recruiting
NCT04797000 Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet… Myelodysplastic Syndromes Active, Not Recruiting
NCT07558434 CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA Severe Aplastic Anemia (SAA) Not Yet Recruiting
NCT07572084 Romiplostim N01 in Chemoradiotherapy-induced Aplastic Anemia Aplastic Anemia Not Yet Recruiting
Phase 1/2
NCT07113743 Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked… Chronic Granulomatous Disease (CGD) Enrolling by Invitation
Phase 1
NCT07321626 Romiplostim N01 for Platelet Recovery After Haploidentical HSCT Acute Myeloid Leukemia Recruiting
NCT06880081 Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP) Primary Immune Thrombocytopenia (ITP) Recruiting
Early Phase 1
NCT07048249 Single Arm Romiplostim to Prevent CIT Ewings Sarcoma Recruiting
Not specified
NCT07612319 Romiplostim for Oral TPO-RA Resistant ITP Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Recruiting
Sponsors Running Romiplostim N01 Trials
Disease Areas
Get alerts when Romiplostim N01 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free